Transvaginal Treatment of Symptomatic Cystocele Grade II-III

NCT ID: NCT02272322

Last Updated: 2017-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will evaluate treatment of symptomatic cystocele grade II-III with Cousin Biomesh and Allium Medical Endofast Reliant. Data about 100 patients will be collected. Follow-up till 3 years after the procedure. Primary endpoint is absence of recurrence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystocele

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cystocele repair with biomesh soft prolaps and endofast reliant

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is a woman
* Patient is between 40 and 90 years old
* Patient has to sign the informed consent form prior to the procedure
* Patient has to agree with the scheduled follow-up visits on month 1, month 6, year 1, year 2 and year 3
* Patient has symptomatic anterior prolapse

Exclusion Criteria

* Recurrence cystocele
* Patient is pregnant
* Patient has a wish to become pregnant
* Patient is taking Plavix, Sintrom, Marcoumar, Marevan, Brilique, Efient, Ticlid, Xarelto, Eliquis or Pradaxa. If intake is stopped prior to procedure, patient is allowed to be included.
* Patient is taking LMWH in a dose of more than 40 mg/day
* Patient has a life expectancy \< 1 year
* Patient has a known connective tissue disease
* Patient has a history of surgery of the anterior vaginal wall or pelvis
* A scheduled hysterectomy during the index-procedure
Minimum Eligible Age

40 Years

Maximum Eligible Age

90 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Slabbaert Koen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Slabbaert Koen

MD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Koen Slabbaert, MD

Role: PRINCIPAL_INVESTIGATOR

RZ Heilig Hart Tienen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

RZ Heilig Hart Tienen

Tienen, Vlaams-Brabant, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BCR-11-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Robot Based Tympanic Tube Placement
NCT03569943 WITHDRAWN NA